New drug cocktail aims to stall aggressive head and neck cancers
NCT ID NCT00494182
Summary
This study tested whether adding the drug sorafenib to two standard chemotherapy drugs (carboplatin and paclitaxel) could better control advanced head and neck cancer that has returned or spread. It involved 48 patients with this difficult-to-treat cancer. The main goal was to see if the three-drug combination could delay the cancer's progression and shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.